Neurology
2 drugs are in development for Myotonic Dystrophy 1.
- Companies
- 2
- Clinical trials
- 10
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Myotonic Dystrophy 1 pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| srp-1003 | Sarepta Therapeutics, Inc. (SRPT) |
Phase 2(1)
| Drug | Company |
|---|---|
| pgn-edodm1 | PepGen Inc. (PEPG) |
About this indication
Myotonic Dystrophy 1 context
Neurology·MeSH: Myotonic Dystrophy (D009223)
Also known as: Atrophica, Myotonia, Atrophicas, Myotonia, Disease, Steinert, Disease, Steinert's, Dystrophia Myotonica 1, Dystrophia Myotonicas, Dystrophica, Myotonia, Dystrophicas, Myotonia, Dystrophies, Myotonic, Dystrophy, Myotonic, Dystrophy, Steinert Myotonic, Myotonica, Dystrophia
Frequently asked questions
How many drugs are in development for Myotonic Dystrophy 1?
BioSniper tracks 2 drugs in development for Myotonic Dystrophy 1 across 2 companies.
How many clinical trials target Myotonic Dystrophy 1?
There are 10 clinical trials targeting Myotonic Dystrophy 1 tracked by BioSniper.